UBS Group
CGON icon

UBS Group’s CG Oncology CGON Stock Holding History

UBS Group’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69.5M Sell
977,695
-334,283
-25% -$21.9M 0.01% 1439
2026
Q1 		$88.8M Sell
1,311,978
-611,768
-32% -$34.7M 0.01% 1141
2025
Q4 		$79.9M Sell
1,923,746
-202,524
-10% -$8.38M 0.01% 1194
2025
Q3 		$85.6M Sell
2,126,270
-102,975
-5% -$2.99M 0.01% 1145
2025
Q2 		$58M Buy
2,229,245
+524,527
+31% +$12.6M 0.01% 1378
2025
Q1 		$41.7M Buy
1,704,718
+690,827
+68% +$19.4M 0.01% 1646
2024
Q4 		$29.1M Buy
1,013,891
+927,357
+1,072% +$31.7M 0.01% 1947
2024
Q3 		$3.26M Buy
86,534
+8,454
+11% +$296K ﹤0.01% 3500
2024
Q2 		$2.46M Buy
78,080
+54,757
+235% +$1.9M ﹤0.01% 3553
2024
Q1 		$1.02M Buy
+23,323
New +$953K ﹤0.01% 4583

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group's CGON Position: Q2 2026 in Review

UBS Group reduced its CG Oncology (CGON) stake by 25% in Q2 2026, selling an estimated $21.9M and leaving 977,695 shares worth $69.5M. The position accounts for 0.01% of the portfolio, ranked #1439.

UBS Group first reported a position in CGON in Q1 2024 and has held it in 10 quarters since. The position peaked at $88.8M in Q1 2026. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • UBS Group held 977,695 shares of CG Oncology worth $69.5M as of Q2 2026.
  • UBS Group sold 334,283 CG Oncology shares in Q2 2026, an estimated $21.9M.
  • CG Oncology made up 0.01% of UBS Group's portfolio in Q2 2026, its #1439 holding.
  • UBS Group first reported a position in CG Oncology in Q1 2024 and has held it in 10 quarters since.
  • UBS Group's CG Oncology position peaked at $88.8M in Q1 2026.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.